SCHEMBL9962914

SCHEMBL9962914

CC(=O)NC(CS)C(C)=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.71
MAPT P10636 1/20 0.71
THRB P10828 1/20 0.71
ALOX15 P16050 1/20 0.71
NFKB1 P19838 1/20 0.71
PTGS2 P35354 1/20 0.71
THPO P40225 1/20 0.71
RECQL P46063 1/20 0.71
BLM P54132 1/20 0.71
SMN1; SMN2 Q16637 1/20 0.71
ALDH1A1 P00352 1/20 0.45
ACE P12821 1/20 0.42
FOLH1 Q04609 1/20 0.35
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM1 P11229 1/20 0.33
MTNR1A P48039 3/20 0.32
MTNR1B P49286 3/20 0.32
GNPAT O15228 1/20 0.32
CTSS P25774 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13295204 1.00 KDM4E (0.71) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL377413 0.86 KDM4E (0.65) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL435838 0.86 KDM4E (0.65) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL12807977 0.86 KDM4E (0.65) KDM4EMAPTTHRBALOX15NFKB1
Acetylcysteine SCHEMBL5291 0.83 MAPT (1.00) KDM4EMAPTTHRBALOX15NFKB1
Acetylcysteine SCHEMBL5292 0.83 MAPT (1.00) KDM4EMAPTTHRBALOX15NFKB1
Acetylcysteine SCHEMBL3923962 0.83 MAPT (1.00) KDM4EMAPTTHRBALOX15NFKB1
Acetylcysteine SCHEMBL149212 0.83 MAPT (1.00) KDM4EMAPTTHRBALOX15NFKB1
Acetylcysteine SCHEMBL3688241 0.83 MAPT (1.00) KDM4EMAPTTHRBALOX15NFKB1
Acetylcysteine SCHEMBL4437350 0.83 MAPT (1.00) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4306550-A1 HYDROGELS FOR CELL THERAPY Adocia (FR) 2024-01-17 EP disclosed
US-20230193244-A1 Methods For Split-Protein Template Assembly By Proximity-Enhanced Reactivity TRIBIOTICA LLC 2023-06-22 US disclosed
WO-2023065551-A1 AGGREGATE FORMED BY MEANS OF ASSEMBLING CHALCOGEN HETEROCYCLIC COMPOUND AND INSULIN, AND PREPARATION METHOD THEREFOR, AND INSULIN ORAL PREPARATION 福州大学 2023-04-27 WO disclosed
WO-2023065550-A1 POLYDISULFIDE POLYPEPTIDE NANOPARTICLE, PREPARATION METHOD THEREFOR, AND POLYPEPTIDE DRUG ORAL PREPARATION 福州大学 2023-04-27 WO disclosed
WO-2022084738-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS Azura Ophthalmics Ltd. (IL) 2022-04-28 WO disclosed
WO-2021045632-A1 CANCER VACCINE VICTORIA LINK LTD (NZ) 2021-03-11 WO disclosed
EP-3201168-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS CELLIX BIO PRIVATE LTD (IN) 2020-03-18 EP disclosed
EP-2928902-B1 CONJUGATE COMPOUNDS VICTORIA LINK LTD (NZ) 2019-07-17 EP disclosed
WO-2019058289-A1 MAIT CELL AGONISTS VICTORIA LINK LIMITED (NZ) 2019-03-28 WO disclosed
WO-2019005966-A1 DENDRIMER DRUG CONJUGATES FOR SUSTAINED INTRA-ARTICULAR DELIVERY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-01-03 WO disclosed
US-7803777-B2 Branched water-soluble polymers and their conjugates BIOGENERIX AG (DE) 2010-09-28 US disclosed
US-7718598-B1 Auxiliary for amide bond formation THE UNIVERSITY OF QUEENSLAND (AU) 2010-05-18 US disclosed
US-7645454-B2 Antibody or antibody fragment which binds specifically to a normal or transformed PSA glycan or glycopeptide SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2010-01-12 US disclosed
US-7635750-B2 Reacting a peptide acyl donor comprising a peptidic backbone made up of two or more amino acids with a peptide amine acceptor under reducing reaction conditions employing an excess of a reducing agent; SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2009-12-22 US disclosed
WO-2009143299-A1 HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS NEUROGESX, INC. (US) 2009-11-26 WO disclosed
WO-2009138437-A1 SALICYLATE CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS GENMEDICA THERAPEUTICS SL (ES) 2009-11-19 WO disclosed
US-20070173636-A1 Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-07-26 US disclosed
US-7186708-B2 Steroidal compounds NICOX S.A. (FR) 2007-03-06 US disclosed
US-20070032405-A1 Branched water-soluble polymers and their conjugates NEOSE TECHNOLOGIES, INC. (US) 2007-02-08 US disclosed
US-20070020224-A1 Protein-proteophore complexes ASCENDIS PHARMA GMBH (DE) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070020224-A1 Protein-proteophore complexes PSMG3, PSME1, PSMD11 KDM4E 3799/4885MAPT 1228/4885THRB 3691/4885
US-20070032405-A1 Branched water-soluble polymers and their conjugates SLC7A5, SLC43A1, SLC7A1 KDM4E 4463/4885MAPT 1895/4885THRB 3685/4885
US-20070173636-A1 Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation TXNL1, NGLY1, RXFP1 KDM4E 2759/4885MAPT 4567/4885THRB 3369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.